Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

White Paper: Redyx: Remdesivir formulation developed at Dr. Reddy’s under the license from Gilead

Remdesivir is the Fi­rst treatment approved by the US FDA for the treatment of COVID-19 in adult and paediatric patients (12 years or older, and weighing at least 40 kg) that require hospitalization. It is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), essential for viral replication. In addition to the US FDA, Remdesivir has been authorized for emergency use for the treatment of COVID-19 by several regulatory agencies, including EMA (European Medicines Agency), MHLW (Ministry of Health, Labour and Welfare), PMDA (Pharmaceuticals and Medical Devices Agency, Japan), and CDSCO (Central Drugs Standard Control Organisation, India).

To know more about our offerings please read the whitepaper on Remdesivir by filling the contact form.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit